Trial Profile
Four-site, Randomized, Parallel Design, Double-blind, Placebo-controlled, 10-week Trial of Donepezil 10 mg Daily for Verbal Memory Problems Among Adults With TBI in the Subacute or Chronic Recovery Period
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Memory disorders
- Focus Therapeutic Use
- Acronyms MEMRI-TBI-D
- 10 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 10 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 12 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.